AAAAAA

   
Results: 1-10 |
Results: 10
LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION, Annals of oncology, 9, 1998, pp. 228-228
CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY, Annals of oncology, 9, 1998, pp. 229-229
RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM
Authors: MCLAUGHLIN P GRILLOLOPEZ AJ LINK BK LEVY R CZUCZMAN MS WILLIAMS ME HEYMAN MR BENCEBRUCKLER I WHITE CA CABANILLAS F JAIN V HO AD LISTER J WEY K SHEN D DALLAIRE BK
Citation: P. Mclaughlin et al., RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM, Journal of clinical oncology, 16(8), 1998, pp. 2825-2833
RITUXAN(TM) - ANTI CD20 MONOCLONAL-ANTIBODY FOR THE TREATMENT OF LYMPHOMA
Authors: GRILLOLOPEZ AJ WHITE CA DALLAIRE BK VARNS C SHEN D MCCLURE A
Citation: Aj. Grillolopez et al., RITUXAN(TM) - ANTI CD20 MONOCLONAL-ANTIBODY FOR THE TREATMENT OF LYMPHOMA, Experimental hematology, 26(8), 1998, pp. 233-233
CLINICAL ACTIVITY OF THE MONOCLONAL-ANTIBODY (MAB) IDEC-C2B8 IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR NHL (R-LG F NHL)/
Authors: GRILLOLOPEZ AJ WHITE CA DALLAIRE BK VARNS C SHEN CD WEAVER R
Citation: Aj. Grillolopez et al., CLINICAL ACTIVITY OF THE MONOCLONAL-ANTIBODY (MAB) IDEC-C2B8 IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR NHL (R-LG F NHL)/, European journal of cancer, 33, 1997, pp. 1179-1179
IDEC-C2B8 (RITUXIMAB) - CLINICAL ACTIVITY IN POOR-PROGNOSIS SUBGROUPSOF RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA
Authors: GRILLOLOPEZ AJ WHITE CA DALLAIRE BK VARNS C SELANDER K MCCLURE A
Citation: Aj. Grillolopez et al., IDEC-C2B8 (RITUXIMAB) - CLINICAL ACTIVITY IN POOR-PROGNOSIS SUBGROUPSOF RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA, Experimental hematology, 25(8), 1997, pp. 406-406
IDEC-C2B8 (RITUXIMAB) ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH RELAPSED LOW-GRADE NON-HODGKINS-LYMPHOMA
Authors: MALONEY DG GRILLOLOPEZ AJ WHITE CA BODKIN D SCHILDER RJ NEIDHART JA JANAKIRAMAN N FOON KA LILES TM DALLAIRE BK WEY K ROYSTON I DAVIS T LEVY R
Citation: Dg. Maloney et al., IDEC-C2B8 (RITUXIMAB) ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH RELAPSED LOW-GRADE NON-HODGKINS-LYMPHOMA, Blood, 90(6), 1997, pp. 2188-2195
ANTI-CD20 CHIMERIC ANTIBODY, IDEC-C2B8 - SAFETY AND CLINICAL ACTIVITYIN THE TREATMENT OF RELAPSED LOW-GRADE OR FOLLICULAR (IWF-A-D) LYMPHOMAS (LG-F NHL)/
Authors: GRILLOLOPEZ AJ DALLAIRE BK VARNS C LEONARD JE SHEN D MCCLURE A ROGERS J ROSENBERG J WEI A SHUEY S
Citation: Aj. Grillolopez et al., ANTI-CD20 CHIMERIC ANTIBODY, IDEC-C2B8 - SAFETY AND CLINICAL ACTIVITYIN THE TREATMENT OF RELAPSED LOW-GRADE OR FOLLICULAR (IWF-A-D) LYMPHOMAS (LG-F NHL)/, Experimental hematology, 24(9), 1996, pp. 691-691
IDEC-C2B8 ANTI-CD20 ANTIBODY - FINAL REPORT ON A PHASE-III PIVOTAL TRIAL IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/
Authors: MCLAUGHLIN P CABANILLAS F GRILLOLOPEZ AJ LINK BK LEVY R CRUCZMAN M HEYMAN MR WILLIAMS M JAIN W BENCEBRUCKLER I HO AD LISTER J ROSENBERG J DALLAIRE BK SHEN D
Citation: P. Mclaughlin et al., IDEC-C2B8 ANTI-CD20 ANTIBODY - FINAL REPORT ON A PHASE-III PIVOTAL TRIAL IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 349-349
IDEC-C2B8 ANTI-CD20 ANTIBODY - RESULTS OF LONG-TERM FOLLOW-UP OF RELAPSED NHL PHASE-II TRIAL PATIENTS
Authors: MALONEY DG GRILLOLOPEZ AJ BODKIN D WHITE C FOON K SCHILDER RJ NEIDHART J JANAKIRAMAN N WALDICHUK C DAVIS T DALLAIRE BK ROYSTON I LEVY R
Citation: Dg. Maloney et al., IDEC-C2B8 ANTI-CD20 ANTIBODY - RESULTS OF LONG-TERM FOLLOW-UP OF RELAPSED NHL PHASE-II TRIAL PATIENTS, Blood, 86(10), 1995, pp. 205-205
Risultati: 1-10 |